BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21555404)

  • 1. Early prediction of proarrhythmic cardiotoxicity in the drug development process.
    Anyukhovsky EP
    Cardiovasc Res; 2011 Jul; 91(1):7-8. PubMed ID: 21555404
    [No Abstract]   [Full Text] [Related]  

  • 2. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
    Mirams GR; Cui Y; Sher A; Fink M; Cooper J; Heath BM; McMahon NC; Gavaghan DJ; Noble D
    Cardiovasc Res; 2011 Jul; 91(1):53-61. PubMed ID: 21300721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the assessment of heart toxicity for all new drugs through translational regulatory science.
    Johannesen L; Vicente J; Gray RA; Galeotti L; Loring Z; Garnett CE; Florian J; Ugander M; Stockbridge N; Strauss DG
    Clin Pharmacol Ther; 2014 May; 95(5):501-8. PubMed ID: 24336137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
    Wiśniowska B; Mendyk A; Fijorek K; Glinka A; Polak S
    J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to determine cardiac ion channels targeted by drugs using the isolated rabbit ventricular wedge model.
    Liu G; Liu T; Cohen D; Liu T; Yan GX
    J Pharmacol Toxicol Methods; 2016; 81():161-70. PubMed ID: 27195944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrocardiographic biomarkers to confirm drug's electrophysiological effects used for proarrhythmic risk prediction under CiPA.
    Vicente J; Hosseini M; Johannesen L; Strauss DG
    J Electrocardiol; 2017; 50(6):808-813. PubMed ID: 28928044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S; Wiśniowska B; Brandys J
    J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender differences in the proarrhythmic potential of QT-prolonging drugs.
    Wolbrette D
    Curr Womens Health Rep; 2002 Apr; 2(2):105-9. PubMed ID: 12116598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it time for in silico simulation of drug cardiac side effects?
    Mirams GR; Noble D
    Ann N Y Acad Sci; 2011 Dec; 1245():44-7. PubMed ID: 22211977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The degree of potassium channel blockade and the risk of torsade de pointes: the truth, nothing but the truth, but not the whole truth.
    Viskin S; Rosovski U
    Eur Heart J; 2005 Mar; 26(6):536-7. PubMed ID: 15713692
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiarrhythmic drugs: from mechanisms to clinical practice.
    Roden DM
    Heart; 2000 Sep; 84(3):339-46. PubMed ID: 10956304
    [No Abstract]   [Full Text] [Related]  

  • 12. Computational approaches to understand the adverse drug effect on potassium, sodium and calcium channels for predicting TdP cardiac arrhythmias.
    Sharifi M
    J Mol Graph Model; 2017 Sep; 76():152-160. PubMed ID: 28756335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Polymorph ventricular tachycardia with torsades de pointes in administration of terodiline (Mictrol)].
    Lycklama à Nijeholt AA
    Ned Tijdschr Geneeskd; 1992 Mar; 136(11):542-3. PubMed ID: 1552962
    [No Abstract]   [Full Text] [Related]  

  • 14. [Ion channels and arrhythmias].
    Borchard U; Hafner D
    Z Kardiol; 2000; 89 Suppl 3():6-12. PubMed ID: 10810780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
    Vicente J; Johannesen L; Hosseini M; Mason JW; Sager PT; Pueyo E; Strauss DG
    PLoS One; 2016; 11(12):e0163619. PubMed ID: 28036334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beat-to-Beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes.
    Thomsen MB; Volders PG; Beekman JD; Matz J; Vos MA
    J Am Coll Cardiol; 2006 Sep; 48(6):1268-76. PubMed ID: 16979017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Torsades de pointes heart arrhythmia caused by terodiline].
    Braadland H
    Tidsskr Nor Laegeforen; 1992 Jan; 112(2):197-8. PubMed ID: 1566246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo.
    Carlsson L; Andersson B; Linhardt G; Löfberg L
    J Cardiovasc Pharmacol; 2009 Jul; 54(1):82-9. PubMed ID: 19528812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk.
    Wible BA; Hawryluk P; Ficker E; Kuryshev YA; Kirsch G; Brown AM
    J Pharmacol Toxicol Methods; 2005; 52(1):136-45. PubMed ID: 15950494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.